Aktis Oncology (AKTS) – What Are Researchers Saying About This Stock?

Posted by Stanley Muller on Oct 20th, 2026

Shares of Aktis Oncology (NASDAQ:AKTS – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $35.62.

A number of research firms have issued reports on AKTS. JPMorgan Chase & Co. boosted their price target on Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Wall Street Zen cut Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. BMO Capital Markets began coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target on the stock. Oppenheimer assumed coverage on Aktis Oncology in a report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Aktis Oncology in a report on Friday, October 2nd.

Get Our Latest Report on Aktis Oncology

Institutional Trading of Aktis Oncology

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Aktis Oncology by 7.9% during the second quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock valued at $73,431,000 after buying an additional 166,231 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Aktis Oncology during the 2nd quarter worth approximately $63,372,000. Jupiter Topco LLC bought a new stake in shares of Aktis Oncology during the 2nd quarter worth approximately $42,359,000. Alyeska Investment Group L.P. purchased a new position in Aktis Oncology during the 2nd quarter valued at $9,347,000. Finally, Mirador Capital Partners LP boosted its holdings in Aktis Oncology by 232.9% during the 3rd quarter. Mirador Capital Partners LP now owns 133,558 shares of the technology company’s stock valued at $2,600,000 after acquiring an additional 93,434 shares during the period. Institutional investors own 28.84% of the company’s stock.

Aktis Oncology Trading Up 0.3%

Aktis Oncology stock opened at $15.11 on Tuesday. Aktis Oncology has a 12 month low of $14.72 and a 12 month high of $34.19. The stock has a fifty day simple moving average of $22.10 and a two-hundred day simple moving average of $22.10. The firm has a market cap of $812.16 million and a price-to-earnings ratio of -18.43.

Aktis Oncology (NASDAQ:AKTS – Get Free Report) last posted its earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to analyst estimates of $2.70 million. On average, equities research analysts forecast that Aktis Oncology will post -1.84 EPS for the current fiscal year.

About Aktis Oncology

(Get Free Report)

Aktis Oncology, Inc is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue.

The company’s platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors.